Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
ICPT Intercept Pharmaceuticals, Inc. monthly Stock Chart
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-7.50 Insider Own2.70% Shs Outstand24.33M Perf Week-7.27%
Market Cap2.40B Forward P/E- EPS next Y-12.42 Insider Trans-4.53% Shs Float17.24M Perf Month-29.47%
Income-173.00M PEG- EPS next Q-3.15 Inst Own81.70% Short Float18.78% Perf Quarter-46.67%
Sales2.80M P/S855.98 EPS this Y-262.50% Inst Trans5.53% Short Ratio5.71 Perf Half Y-58.95%
Book/sh28.00 P/B3.52 EPS next Y-35.70% ROA-32.20% Target Price324.13 Perf Year-51.05%
Cash/sh28.60 P/C3.44 EPS next 5Y7.00% ROE-34.10% 52W Range90.00 - 314.88 Perf YTD-34.04%
Dividend- P/FCF- EPS past 5Y0.00% ROI-49.00% 52W High-68.72% Beta-
Dividend %- Quick Ratio21.80 Sales past 5Y- Gross Margin- 52W Low9.46% ATR9.16
Employees136 Current Ratio21.80 Sales Q/Q0.00% Oper. Margin- RSI (14)35.44 Volatility9.36% 9.22%
OptionableYes Debt/Eq0.00 EPS Q/Q-24.30% Profit Margin- Rel Volume1.63 Prev Close102.34
ShortableYes LT Debt/Eq0.00 EarningsFeb 29 BMO Payout- Avg Volume567.32K Price98.51
Recom2.10 SMA20-13.99% SMA50-30.44% SMA200-51.42% Volume925,122 Change-3.74%
Dec-04-15Initiated Wells Fargo Market Perform
Nov-18-15Reiterated Oppenheimer Outperform $375 → $375
Nov-11-15Reiterated FBR Capital Mkt Perform $273 → $192
Oct-28-15Downgrade BofA/Merrill Neutral → Underperform
Aug-13-15Initiated Morgan Stanley Underweight $165
May-21-15Initiated Barclays Overweight $425
May-19-15Downgrade BofA/Merrill Buy → Neutral
Apr-17-15Initiated UBS Buy $465
Mar-17-15Initiated MLV & Co Hold $273
Jan-28-15Reiterated Oppenheimer Outperform $499 → $375
Dec-04-14Initiated Robert W. Baird Outperform $258
Dec-03-14Reiterated FBR Capital Underperform $125 → $99
Nov-10-14Reiterated FBR Capital Underperform $172 → $125
Aug-15-14Initiated FBR Capital Underperform $172
Aug-12-14Reiterated RBC Capital Mkts Outperform $425 → $500
Jul-01-14Initiated RBC Capital Mkts Outperform $425
May-15-14Initiated Summer Street Research Buy $650
May-08-14Reiterated Oppenheimer Outperform $525 → $499
Mar-18-14Reiterated Needham Buy $320 → $500
Mar-14-14Reiterated Oppenheimer Outperform $360 → $525
Feb-04-16 04:05PM  Intercept to Present at Upcoming Investor Conferences GlobeNewswire
Feb-03-16 12:00AM  Seven $1 billion-plus drugs seen reaching market in 2016 Reuters
Jan-29-16 11:11AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers +6.96%
08:56AM  Morgan Stanley Upgrades Intercept Pharma, Maintains $100 Target
06:53AM  Intercept Pharma upgraded by Morgan Stanley
Jan-27-16 06:03AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Jan-07-16 12:16PM  Intercept Pharmaceuticals Sold Off in December, and Here's Why at Motley Fool
Jan-05-16 11:36AM  Stick With Biotech in 2016? at Barrons.com
11:21AM  The Top 5 Mid-Cap Biotechnology Stocks for 2016 (ALNY, ICPT) at Investopedia
Dec-23-15 02:48PM  Biotech Stock Roundup: KaloBios Removes CEO Shkreli, Actelion PAH Drug Approved
Dec-18-15 04:45PM  Intercept (ICPT) Down on Delay in FDA's Verdict on Lead Drug -5.95%
04:44PM  BioMarin, Intercept Pharma Drugs Face FDA Delays at Investor's Business Daily
12:18PM  Why Are These Stocks Among Todays Losers? at Insider Monkey
09:45AM  Intercept Pharma Disappoints on FDA Extension at 24/7 Wall St.
Dec-17-15 05:00PM  FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC GlobeNewswire
08:39AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : December 17, 2015
Dec-15-15 11:27AM  Why Are These Five Stocks Surging on Tuesday? at Insider Monkey +16.85%
Dec-12-15 07:03AM  2015's Worst Clinical Failures at Motley Fool
Dec-11-15 05:02PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders
07:05AM  Gino Santini and Daniel Welch Elected to Board of Directors of Intercept Pharmaceuticals GlobeNewswire
Dec-08-15 01:17PM  INTERCEPT PHARMACEUTICALS INC Financials
08:29AM  Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas
Dec-07-15 07:05AM  Intercept Pharmaceuticals Announces Initiation of Prospective Trial to Explore Effect of Combined OCA and Statin Therapy on Lipid Metabolism in NASH Patients GlobeNewswire
Dec-02-15 04:05PM  Intercept to Present at the Oppenheimer Healthcare Conference GlobeNewswire -5.35%
11:32AM  Is Caseys General Stores, Inc. (CASY) a Good Buy? at Insider Monkey
11:07AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 2, 2015
Dec-01-15 04:32PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
03:43PM  Intercept (ICPT) Initiates Study on Another Bile Acid Analog
Nov-30-15 04:05PM  Intercept Pharmaceuticals Initiates Phase 1 Study of INT-767, a Dual FXR and TGR5 Agonist GlobeNewswire
Nov-27-15 03:42PM  Is Mercadolibre Inc (MELI) A Good Stock To Buy? at Insider Monkey
Nov-23-15 10:37AM  fix- Is Intercept Pharmaceuticals Inc (ICPT) A Good Stock To Buy? Version 1.7 at Insider Monkey +6.73%
Nov-14-15 02:07PM  Intercept Presents New PBC Data at AASLD 2015 GlobeNewswire
10:00AM  Intercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT Trial of Obeticholic Acid in Nonalcoholic Steatohepatitis at AASLD 2015 GlobeNewswire
Nov-12-15 08:07AM  BioCryst and Intercept Drive Biotechnology Subgroup
Nov-10-15 10:29AM  IBB Overcomes the Market Trend and Gains Marginally +7.11%
Nov-09-15 01:31PM  Edited Transcript of ICPT earnings conference call or presentation 9-Nov-15 1:00pm GMT +8.82%
08:55AM  Intercept (ICPT) Posts Narrower-Than-Expected Loss in Q3
08:07AM  Myriad Genetics: Top Performer in the Biotechnology Subgroup
07:36AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:35AM  Intercept reports 3Q loss
07:07AM  Q3 2015 Intercept Pharmaceuticals Inc Earnings Release - Before Market Open
07:05AM  Intercept Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Business Update GlobeNewswire
Nov-06-15 07:01PM  After jobs, Street eyes consumer at CNBC
03:25PM  Will Puma Biotechnology (PBYI) Surprise in Q3 Earnings?
02:40PM  Will Intercept (ICPT) Beat Estimates in Q3 Earnings?
Nov-04-15 10:27AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : November 4, 2015
Nov-03-15 07:05AM  Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting GlobeNewswire +7.36%
Nov-02-15 04:05PM  Intercept to Report Third Quarter 2015 Financial Results on November 9th GlobeNewswire +7.63%
Oct-30-15 09:07AM  ISIS Rose 11.4%, Helped the Biotechnology Subgroups Performance
08:19AM  Why biotech could be on the verge of a rebound
Oct-29-15 09:54AM  Morgan Stanley Sees 33% Downside At Intercept Pharma, Increased Risk
Oct-28-15 01:53PM  Intercept Pharmaceuticals, Inc. Value Analysis (NASDAQ:ICPT) : October 28, 2015
12:05PM  Intercept Pharma NASH Drug Disappoints In Japan at Investor's Business Daily
08:29AM  Intercept Pharma is crashing
07:30AM  Intercept Pharmaceuticals Announces Results of Phase 2 Trial of OCA in NASH Patients in Japan GlobeNewswire
Oct-27-15 09:32PM  Trending Now: ICPT
Oct-24-15 02:04PM  The Bottom Ten Stocks of XBI Outperform on October 8
Oct-21-15 09:30AM  These Five Biotech Stocks Ranked Among This UK-based Funds Favorites at Insider Monkey
Oct-15-15 02:06PM  Alnylam and Intercept Drive IBBs Biotechnology Subgroup +5.51%
Oct-09-15 08:45AM  One More Thing Investors Should Know About Asset Bubbles at Forbes
Oct-08-15 10:43AM  Biotech Restores Some of Its Lost Ground as the Market Rises +6.24%
Oct-07-15 05:13PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendment or Waiver to C +8.00%
12:07PM  IBBs Top Ten Mid-Cap Stocks Underperformed Last Week
Sep-28-15 07:05AM  Intercept Pharmaceuticals Announces Initiation of REGENERATE Trial for Obeticholic Acid in NASH Patients With Advanced Liver Fibrosis GlobeNewswire -5.63%
Sep-15-15 04:25PM  Raptor Crushed by Liver Disease Data, Hits 52-Week Low
Sep-14-15 11:10AM  Raptor Pharma Drug Flops In Fatty Liver Disease at Investor's Business Daily
Sep-08-15 08:32AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events +5.93%
07:05AM  Intercept to Present at the Baird Healthcare Conference GlobeNewswire
Sep-04-15 11:34AM  Benchmark Indexes Continue to Outperform IBB and XBI
Sep-02-15 01:01PM  ICPT and XON Put Pressure on XBIs Biotechnology Sector
Sep-01-15 05:54PM  Intercept's (ICPT) OCA Under Priority Review in the U.S.
06:51AM  Intercept Pharma Could Be Bought for $493 a Share at Barrons.com
Aug-31-15 07:05AM  FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis GlobeNewswire
Aug-20-15 09:32PM  4 Reasons Intercept Pharmaceuticals Should Be on Your Radar at Investopedia -7.10%
Aug-13-15 12:11PM  Intercept Pharma Dips As Analyst Doubts NASH Market at Investor's Business Daily -7.89%
Aug-07-15 07:27AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Aug-06-15 02:31PM  Intercept Pharmaceuticals' Q2 Loss Wider than Expected - Analyst Blog -7.75%
Aug-05-15 11:55PM  Edited Transcript of ICPT earnings conference call or presentation 5-Aug-15 8:30pm GMT
06:55PM  Intercept reports 2Q loss
04:17PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition
04:05PM  Intercept Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Business Update GlobeNewswire
07:07AM  Q2 2015 Intercept Pharmaceuticals Inc Earnings Release - After Market Close
Aug-04-15 01:15PM  Intercept Pharmaceuticals (ICPT): Q2 Earnings Preview - Analyst Blog
Jul-29-15 04:05PM  Intercept to Report Second Quarter 2015 Financial Results on August 5 and Present at Upcoming Conferences GlobeNewswire
Jul-21-15 04:05PM  Intercept Pharmaceuticals Appoints Richard Kim as Senior Vice President, Commercial Head of U.S. GlobeNewswire
Jul-09-15 05:26PM  Gilead's next target?
Jul-07-15 09:45AM  Intercept Pharmaceuticals Makes a Breakthrough at Investopedia
Jul-02-15 05:56PM  DALCOMP NEGOTIATED CALENDAR Reuters
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta - Press Releases
Jul-01-15 11:29AM  Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress - Analyst Blog
Jun-30-15 02:35PM  Intercept Pharmaceuticals Files for OCA in U.S. and Europe - Analyst Blog
06:02AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Jun-29-15 04:05PM  Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis GlobeNewswire -5.99%
Jun-22-15 06:00AM  Intercept Pharmaceuticals Appoints Juan Carlos Lopez-Talavera, M.D., Ph.D. as Senior Vice President of Medical Affairs GlobeNewswire
Jun-17-15 10:30PM  Edited Transcript of ICPT earnings conference call or presentation 11-May-15 1:45pm GMT
08:20AM  LLTP Shares Attractive On Rolling NDA Submission - 300 Percent in Potential Upside
Jun-11-15 01:36PM  Edited Transcript of ICPT presentation 10-Jun-15 10:20pm GMT
May-26-15 08:30AM  4 Big Biotech Companies to Sell Now at TheStreet
May-23-15 08:10AM  What You May Have Missed in Biotech: Eye Drug Fails, Ear Drug Flops, and Herpes Drug Succeeds at Forbes
May-22-15 09:02PM  Will This Drug Beat Gilead to Market in NASH? at Investopedia
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid (OCA), a bile acid analog that completed Phase III clinical trial for the treatment of primary biliary cirrhosis; is in Phase III clinical trial for the treatment of nonalcoholic steatohepatitis; is in Phase 2 clinical trial for primary sclerosing cholangitis; and is in Phase I clinical trial for the treatment of biliary atresia. The company's product candidates in preclinical stage include INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of fibrosis; and INT-777, an orally administered TGR5 agonist used in treating type 2 diabetes. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McMinn RachelChief Strategy OfficerFeb 01Sale103.5612813,2567,621Feb 03 09:00 PM
Duncan Barbara GayleChief Financial OfficerJan 04Sale145.9046868,28324,892Jan 05 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJan 04Sale145.9053377,76740,911Jan 05 09:00 PM
Pruzanski MarkCEO & PresidentJan 04Sale145.902,126310,191529,556Jan 05 09:00 PM
McMinn RachelChief Strategy OfficerJan 04Sale145.9046968,4297,749Jan 05 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentDec 18Option Exercise17.5011,426199,99139,821Dec 22 10:00 AM
Shapiro DavidCMO and EVP - DevelopmentDec 15Option Exercise8.673,50030,33331,895Dec 17 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentDec 15Sale157.403,500550,90028,395Dec 17 09:00 PM
Bright LisaSee RemarksNov 25Sale182.961,150210,40912,428Nov 30 09:00 PM
WILLIAMS NICOLEDirectorNov 20Option Exercise9.829739,5571,935Nov 23 09:01 PM
WILLIAMS NICOLEDirectorNov 20Sale167.00973162,491962Nov 23 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentNov 16Option Exercise8.673,50030,33332,659Nov 18 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentNov 16Sale178.534,264761,23728,395Nov 18 09:00 PM
VEITINGER KLAUS R DRDirectorNov 10Option Exercise21.501,00021,5003,166Nov 12 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentNov 10Option Exercise8.673,50030,33332,659Nov 12 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentNov 10Sale204.153,500714,52529,159Nov 12 09:00 PM
VEITINGER KLAUS R DRDirectorNov 10Sale198.251,000198,2502,166Nov 12 09:01 PM
McMinn RachelChief Strategy OfficerNov 02Sale160.2412520,0298,218Nov 04 09:00 PM
AKKARAJU SRINIVASDirectorOct 28Option Exercise21.501,25026,8759,892Oct 30 11:59 AM
WILLIAMS NICOLEDirectorOct 20Option Exercise9.829749,5671,936Oct 22 09:00 PM
WILLIAMS NICOLEDirectorOct 20Sale182.22974177,482962Oct 22 09:00 PM
Pruzanski MarkCEO & PresidentOct 02Sale159.0416726,560526,814Oct 05 09:01 PM
Duncan Barbara GayleChief Financial OfficerOct 02Sale159.04548,58824,062Oct 05 09:02 PM
Duncan Barbara GayleChief Financial OfficerOct 01Option Exercise8.671,0008,66723,818Oct 05 09:02 PM
Duncan Barbara GayleChief Financial OfficerOct 01Sale163.391,000163,39024,116Oct 05 09:02 PM
WILLIAMS NICOLEDirectorSep 21Option Exercise9.829739,5571,935Sep 23 09:00 PM
WILLIAMS NICOLEDirectorSep 21Sale194.82973189,560962Sep 23 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentSep 15Option Exercise8.678,79476,21527,027Sep 17 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentSep 15Sale191.283,500669,48023,527Sep 17 09:00 PM
VEITINGER KLAUS R DRDirectorSep 09Option Exercise21.5050010,7502,666Sep 11 09:00 PM
VEITINGER KLAUS R DRDirectorSep 09Sale198.2550099,1252,166Sep 11 09:00 PM
WILLIAMS NICOLEDirectorAug 20Option Exercise9.829749,5671,936Aug 24 09:00 PM
WILLIAMS NICOLEDirectorAug 20Sale206.85974201,472962Aug 24 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 17Option Exercise8.673,50030,33322,505Aug 19 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 17Sale209.374,272894,42918,233Aug 19 09:00 PM
VEITINGER KLAUS R DRDirectorAug 03Option Exercise21.5050010,7502,666Aug 05 09:00 PM
VEITINGER KLAUS R DRDirectorAug 03Sale261.17500130,5852,166Aug 05 09:00 PM
McMinn RachelChief Strategy OfficerJul 31Sale262.0912733,2864,293Aug 04 09:02 PM
Fundaro PaoloDirectorJul 24Sale285.00582165,8708,221Jul 24 09:12 PM
WILLIAMS NICOLEDirectorJul 20Option Exercise9.829739,5571,935Jul 22 09:00 PM
WILLIAMS NICOLEDirectorJul 20Sale279.01973271,477962Jul 22 09:00 PM
Pruzanski MarkCEO & PresidentJul 10Option Exercise8.6712,500108,334519,514Jul 14 09:00 PM
Pruzanski MarkCEO & PresidentJul 10Sale250.0012,5003,125,000507,014Jul 14 09:00 PM
Adorini LucianoChief Scientific OfficerJul 06Option Exercise21.294,06786,58114,776Jul 08 09:00 PM
Adorini LucianoChief Scientific OfficerJul 06Sale579.934,0672,358,59110,709Jul 08 09:00 PM
Pruzanski MarkCEO & PresidentJul 02Sale236.2615837,328507,014Jul 07 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 02Sale236.29851201,08319,005Jul 07 09:00 PM
Duncan Barbara GayleChief Financial OfficerJul 02Sale236.265312,52218,768Jul 07 09:00 PM
Duncan Barbara GayleChief Financial OfficerJul 01Option Exercise8.671,0008,66718,523Jul 06 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 01Option Exercise8.673,50030,33322,014Jul 06 09:00 PM
Duncan Barbara GayleChief Financial OfficerJul 01Sale242.101,000242,10017,523Jul 06 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 01Sale238.663,781902,37818,233Jul 06 09:00 PM
WILLIAMS NICOLEDirectorJun 22Option Exercise9.829749,5671,936Jun 24 09:00 PM
WILLIAMS NICOLEDirectorJun 22Sale265.14974258,246962Jun 24 09:00 PM
VEITINGER KLAUS R DRDirectorJun 10Option Exercise21.503918,4072,557Jun 12 09:00 PM
VEITINGER KLAUS R DRDirectorJun 10Sale238.2139193,1402,166Jun 12 09:00 PM
Adorini LucianoChief Scientific OfficerJun 08Option Exercise8.674,00034,66714,060Jun 10 09:00 PM
Adorini LucianoChief Scientific OfficerJun 08Sale248.404,000993,59810,060Jun 10 09:00 PM
Pruzanski MarkCEO & PresidentJun 03Option Exercise17.766,561116,550502,304Jun 05 09:00 PM
WILLIAMS NICOLEDirectorMay 20Option Exercise9.829739,5571,935May 22 09:00 PM
WILLIAMS NICOLEDirectorMay 20Sale260.20973253,175962May 22 09:00 PM
AKKARAJU SRINIVASDirectorMay 19Option Exercise21.501,00021,5008,642May 22 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMay 15Option Exercise8.673,50030,33322,793May 19 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentMay 15Sale306.904,2791,313,24418,514May 19 09:01 PM
Pruzanski MarkCEO & PresidentMay 14Option Exercise8.675,00043,334500,743May 18 09:00 PM
Pruzanski MarkCEO & PresidentMay 14Sale300.005,0001,500,000495,743May 18 09:00 PM
VEITINGER KLAUS R DRDirectorMay 11Option Exercise21.503918,4072,557May 13 09:00 PM
VEITINGER KLAUS R DRDirectorMay 11Sale279.07391109,1172,166May 13 09:00 PM
Adorini LucianoChief Scientific OfficerMay 06Option Exercise8.674,00034,66714,060May 08 09:00 PM
Adorini LucianoChief Scientific OfficerMay 06Sale259.974,0001,039,86310,060May 08 09:00 PM
Pruzanski MarkCEO & PresidentMay 01Option Exercise8.6712,500108,334508,243May 05 09:00 PM
Pruzanski MarkCEO & PresidentMay 01Sale253.5612,5003,169,495495,743May 05 09:00 PM
McMinn RachelChief Strategy OfficerMay 01Sale255.12503128,3274,420Jul 17 09:00 PM
WILLIAMS NICOLEDirectorApr 20Option Exercise9.829749,5671,936Apr 22 09:00 PM
WILLIAMS NICOLEDirectorApr 20Sale278.50974271,259962Apr 22 09:00 PM
VEITINGER KLAUS R DRDirectorApr 10Option Exercise21.503918,4072,557Apr 14 09:00 PM
VEITINGER KLAUS R DRDirectorApr 10Sale272.10391106,3912,166Apr 14 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentApr 02Sale277.70843234,10219,293Apr 03 09:01 PM
Pruzanski MarkCEO & PresidentApr 02Sale277.7015743,599495,743Apr 03 09:00 PM
Duncan Barbara GayleChief Financial OfficerApr 02Sale277.703910,83017,523Apr 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentApr 01Option Exercise8.822,33420,58022,752Apr 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentApr 01Sale274.462,616718,00020,136Apr 03 09:01 PM
Duncan Barbara GayleChief Financial OfficerMar 27Sale289.821,000289,81716,264Apr 01 10:00 AM
SILVERSTEIN JONATHANDirectorMar 26Sale286.75157,20045,076,4421,120,324Mar 30 03:59 PM
ORBIMED ADVISORS LLCDirectorMar 26Sale286.75157,20045,076,4421,120,324Mar 30 03:58 PM
SILVERSTEIN JONATHANDirectorMar 25Sale270.232,800756,6441,277,524Mar 25 07:34 PM
ORBIMED ADVISORS LLCDirectorMar 25Sale270.232,800756,6441,277,524Mar 25 07:28 PM
SILVERSTEIN JONATHANDirectorMar 24Sale272.0045,60012,402,9951,280,324Mar 25 07:34 PM
ORBIMED ADVISORS LLCDirectorMar 24Sale272.0045,60012,402,9951,280,324Mar 25 07:28 PM
SILVERSTEIN JONATHANDirectorMar 23Sale275.18159,40043,863,0671,325,924Mar 25 07:34 PM
ORBIMED ADVISORS LLCDirectorMar 23Sale275.18159,40043,863,0671,325,924Mar 25 07:28 PM
WILLIAMS NICOLEDirectorMar 20Option Exercise9.829739,5571,935Mar 24 09:00 PM
WILLIAMS NICOLEDirectorMar 20Sale305.36973297,115962Mar 24 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 16Option Exercise10.403,50036,40022,296Mar 18 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 16Sale286.903,5001,004,14018,796Mar 18 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 12Option Exercise8.675,00043,33423,796Mar 16 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 12Sale285.995,0001,429,93818,796Mar 16 09:00 PM
VEITINGER KLAUS R DRDirectorMar 10Option Exercise21.503918,4072,557Mar 12 09:00 PM
VEITINGER KLAUS R DRDirectorMar 10Sale262.06391102,4652,166Mar 12 09:00 PM
VEITINGER KLAUS R DRDirectorFeb 24Option Exercise21.5063213,5882,798Feb 26 09:00 PM